Molecular biomarkers of sintilimab plus lenvatinib in hepatitis-B-virus-associated hepatocellular carcinoma

Table 1 Patients’ baseline characteristics evaluated by modified Response Evaluation Criteria in Solid Tumors, n (%)

Characteristic	Response group (CR + PR, n = 22)	Non-response group (SD + PD, n = 11)	P value
Median age (year)			0.488
< 60	13 (59)	5 (46)
≥ 60	9 (41)	6 (54)
Sex			0.033a
Male	21 (95)	7 (64)
Female	1 (5)	4 (36)
ECOG PS			0.017a
0	18 (82)	4 (36)
1	4 (18)	7 (64)
BCLC stage			1.000
B	11 (50)	5 (45)
C	11 (50)	6 (55)
Tumor number			1.000
1	12 (55)	6 (55)
2-3	6 (27)	3 (27)
≥ 4	4 (18)	2 (18)
Size of the largest tumor (cm)			0.593
< 5	3 (14)	2 (18)
5-10	10 (45)	3 (27)
≥ 10	9 (41)	6 (55)
Serum alpha-fetoprotein level			0.488
< 400 ng/mL	13 (59)	5 (45)
≥ 400 ng/mL	9 (41)	6 (55)
Conversion to surgery			0.132
Yes	11 (50)	2 (18)
No	11 (50)	9 (82)

^aP < 0.05. P values for differences between two groups were obtained by Fisher’s exact test.

CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease; ECOG PS: Eastern Cooperative Oncology Group performance status; BCLC: Barcelona Clinic Liver Cancer.